Bridging the gap: how do we enroll more racial-ethnic minority patients in hematological drug trials?

Click to increase image sizeClick to decrease image size

Declaration of interests

S Ailawadhi has had consultancy with GSK, Sanofi, BMS, Takeda, Beigene, Janssen, Regeneron, Cellectar, Pfizer and received institutional research funding from GSK, BMS, Pharmacyclics, Amgen, Janssen, Cellectar, AbbVie, Ascentage, and Sanofi.

The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

Reviewer disclosures

Peer reviewers on this manuscript have no relevant financial relationships or otherwise to disclose.

Additional information

Funding

This paper was not funded.